Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.25
Bid: 44.50
Ask: 46.00
Change: -0.40 (-0.89%)
Spread: 1.50 (3.371%)
Open: 44.60
High: 45.25
Low: 44.50
Prev. Close: 45.10
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Mon, 22nd Feb 2021 11:01

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Clear Leisure, up 67% at 2.09 pence, 12-month range 1.25p-2.60p. The technology sector-focused investor raises GBP1.0 million through a placing, with the cash going towards accelerating its cryptocurrency plans. Clear Leisure eyes entry into cloud mining contracts and setting up a new bitcoin mining operation in Italy.

----------

Avacta Group, up 10% at 201.40 pence, 12-month range 13.00p-224.88p. The developer of Affimer biotherapeutics and reagents notes press reports in regard to the UK government's take-up of its lateral flow SARS-CoV-2 rapid antigen test. Avacta is now progressing to a full clinical validation with a larger number of patient samples in order to obtain a CE mark for the test for professional use, aiming to bring the test to market

----------

Directa Plus, up 13% at 146.40 pence, 12-month range 46.25p-160.00p. Directa seals a supply agreement and a strategic research & development deal with Nevada, US-based lithium firm NexTech Batteries. The producer and supplier of graphene nanoplatelets based products says the supply agreement has an initial duration of three years, with an option to extend for an additional two years by mutual agreement. The research & development deal also has a duration of three years and provides for joint laboratory activities, with the intention of developing new specific grades of G+ graphene nanoplatelets for a next generation of NexTech's Li-S batteries.

----------

AIM - LOSERS

----------

President Energy, down 15% at 2.07 pence, 12-month range 1.20p-3.90p. The South America-focused energy company expects to post a revenue fall of 32% to USD28 million for 2020. Says average net production in 2020 rose 12%, however.

----------

Image Scan Holdings, down 11% at 2.44 pence, 12-month range 1.00p-3.50p. The X-ray imaging firm's order intake is being hurt by Covid-19, particularly in its security segment. Image Scan says large, multi-unit orders are being delayed.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
1 Jun 2021 11:16

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

Read more
28 May 2021 11:29

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

Read more
28 May 2021 07:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

Read more
10 May 2021 11:13

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Read more
22 Apr 2021 12:17

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Read more
20 Apr 2021 15:18

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

Read more
20 Apr 2021 12:17

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Read more
20 Apr 2021 11:35

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

Read more
15 Apr 2021 14:56

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 13:53

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

Read more
6 Apr 2021 11:03

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

Read more
25 Mar 2021 15:57

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Read more
9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

Read more
9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.